Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004874 · ClinicalTrials.gov registry record · Phase 2
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT01004874 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 80 participants.
The verdict
NCT01004874, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a phase II study of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and topotecan in grade IV malignant glioma patients.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- DRUG Topotecan
- RADIATION Radiation Therapy (XRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-12-30 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004874
The ClinicalTrials.gov registry entry for NCT01004874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01004874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004874 about?
NCT01004874 is a clinical study titled "Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma". This is a phase II study of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and topotecan in grade IV malignant glioma patients.
What is the current status of trial NCT01004874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2009-12-30. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT01004874?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Topotecan (DRUG), Radiation Therapy (XRT) (RADIATION).
Who is sponsoring clinical trial NCT01004874?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.